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Abstract Aquaporin-4 antibody (AQP4-Ab)-positive
neuromyelitis optica spectrum disorder (NMOSD) is a rare
but often severe autoimmune disease with median onset
around 40 years of age. We report characteristics of three
very-late-onset NMOSD (including complete NMO) pa-
tients[75 years of age, in whom this diagnosis initially
seemed unlikely because of their age and age-associated
concomitant diseases, and briefly review the literature. All
three patients, aged 79, 82 and 88 years, presented with a
spinal cord syndrome as the first clinical manifestation of
AQP4-Ab-positive NMOSD. They all had severe relapses
unless immunosuppressive therapy was initiated, and one
untreated patient died of a fatal NMOSD course. Two pa-
tients developed side effects of immunosuppression. We
conclude that a first manifestation of NMOSD should be
considered even in patients beyond the age of 75 years with
a compatible syndrome, especially longitudinally extensive
myelitis. Early diagnosis and treatment are feasible and
highly relevant. Special attention is warranted in the
elderly to recognize adverse effects of immunosuppressive
therapies as early as possible.
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Abbreviations
AQP4 Aquaporin 4
AQP4-Ab Aquaporin-4 antibodies
CSF Cerebrospinal fluid
EDSS Expanded disability status scale (0–10 points,
0 = normal, 10 = death due to MS)
IgG Immunoglobulin G
MRC Medical Research Council (scale for muscle
strength 0–5, 5 = full strength)
MRI Magnetic resonance imaging
NEMOS Neuromyelitis Optica Study Group
NMO Neuromyelitis optica
NMOSD Neuromyelitis optica spectrum disorder
OCB Oligoclonal bands
Background
Neuromyelitis optica (NMO) is a rare but often severely
disabling autoimmune disease of the central nervous sys-
tem affecting predominantly women, most frequently in
their 30s to 40s [1, 2]. Aquaporin-4 antibodies (AQP4-Ab)
are present in about 80 % of NMO patients and in a subset
of patients with isolated longitudinally extensive myelitis
or isolated optic neuritis, who are then considered to have
formes frustes of NMO. NMO and its incomplete forms are
referred to as NMO spectrum disorders (NMOSD) [3].
AQP4-Ab are highly specific for NMOSD, even in the
elderly [4].
Case series
Case 1
A 79-year-old man was admitted to a municipal hospital
with a bilateral sensory level below T3 and gait ataxia
since the last month (EDSS 6.5). Magnetic resonance
imaging (MRI) revealed spinal cord lesions at vertebra C1-
4, at T3/4, and brain microangiopathy. Cerebrospinal fluid
(CSF) analysis showed mildly increased albumin, but
normal immunoglobulin G (IgG), negative oligoclonal
bands (OCB), and a normal cell count. Autoimmune
myelitis was suspected, and symptoms improved after in-
travenous glucocorticoids (EDSS 5.0).
Four months later, a second attack occurred with severe
left-sided optic neuritis and worsening of sensorimotor
symptoms (EDSS 9.0). MRI revealed an enlarged myelon
lesion (medulla oblongata to vertebra C5, partially gado-
linium-enhancing). CSF analysis showed pleocytosis (32/
ll). Symptoms improved after intravenous steroids (EDSS
8.0).
After another month, a third attack occurred with dys-
phagia, a high-cervical transverse spinal cord syndrome
with marked tetraparesis, and another severe optic neuritis
(blindness in left eye; EDSS 9.0). He was admitted to a
university hospital. MRI revealed a lesion extending over
the entire myelon and brainstem involvement (Fig. 1a).
CSF analysis showed 43 cells/ll including granulocytes.
AQP4-Ab were positive in serum and CSF (DMFI 816 and
181, respectively, FACS-based assay), and diagnosis of
AQP4-Ab positive NMO [5] as part of NMOSD [3] was
established. Intravenous steroids were given, followed by
plasma exchange, without improvement. After further de-
terioration with respiratory insufficiency because of high
cervical myelon involvement (EDSS 9.5) and pneumonia,
he required intensive care and died shortly thereafter.
Case 2
An 88-year-old woman experienced numbness in her legs
and moderate paraparesis with impaired gait since 2 days.
Spinal MRI demonstrated a myelon lesion from vertebra
T6-9 (Fig. 1b-c), which was initially attributed to com-
pression myelopathy because of concomitant vertebral disc
protrusions. Without specific treatment, she recovered
partially and was able to walk with a crutch for[100 m
(EDSS 6.0). Her previous medical history was negative for
prior potential attacks, but included a transient ischemic
attack with dysarthria for\24 h 1.5 years before; cerebral
MRI had not shown inflammatory lesions.
Eight months later, she was re-admitted with an anew
gait impairment and sensorimotor paraparesis (MRC grade
2–3, EDSS 8.5). MRI demonstrated a new T2 hyperintense
myelon lesion from vertebra T10–T12 with central gado-
linium enhancement (Fig. 1d–f). Visual evoked potentials
had low amplitudes bilaterally and normal latencies. CSF
showed mild lymphomonocytic pleocytosis and positive
OCB. Serum AQP4-Ab were positive (1:3200, cell-based
immunofluorescence assay), as were antibodies against
dsDNA and cardiolipin. Diagnosis of AQP4-Ab positive
NMOSD was established, and the first myelon lesion was
retrospectively attributed also to NMOSD. Treatment in-
cluded methylprednisolone 5 9 1 g, a second cycle of
5 9 2 g, and then plasma exchange. She recovered par-
tially (EDSS 7.0). Azathioprine was given up to 150 mg/d
(2.2 mg/kg); thiopurine S-methyltransferase activity was
normal. After 5 months of therapy, regular blood testing
revealed pancytopenia. Azathioprine was stopped, but
thrombocytopenia persisted and she died of intestinal
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bleeding. In addition to azathioprine as a likely cause for
bone marrow suppression and thrombocytopenia, she had
also developed anti-platelet antibodies.
Case 3
A woman was admitted shortly before her 83rd birthday
with numbness and weakness in her right arm, impaired
sensation below T10 bilaterally, and high-graded para-
paresis since 2 days (EDSS 8.0). Her previous medical
history and family history was unremarkable, in particular,
for previous attack-like clinical events or immunological
disease. Infectious myelitis was suspected, and antimicro-
bial treatment started.
MRI demonstrated two longitudinally extensive
myelon lesions (foramen magnum to vertebra C4, T6-9),
both with dorsal gadolinium enhancement (Fig. 1g–i),
but no inflammatory brain lesions. CSF analysis showed
mild pleocytosis (10 cells/ll, 3 % neutrophils) with one
CSF-restricted band, negative MRZ reaction, and nor-
mal IgG and albumin ratios. An extensive search for
microbial pathogens in serum and CSF was negative.
She reported no visual symptoms, but visual evoked
potentials demonstrated delayed P100 latencies
bilaterally with normal amplitudes. Screening for
rheumatic disease showed high titers for antinuclear
antibodies (1:12,800, negative for standard ENA panel)
without further clinical or laboratory evidence of
rheumatologic disease.
Autoimmune myelitis being suspected, she received
methylprednisolone (5 9 500 mg i.v.). Serum AQP4-Ab
turned out positive (1:320, immunofluorescence assay), and
diagnosis of AQP4-Ab positive NMOSD was established.
Since there was no improvement and the patient refused
plasma exchange, she received a second cycle of methyl-
prednisolone (5 9 2 g i.v. with oral taper), and azathio-
prine was started (up to 125 mg/d). She improved
continuously and was able to walk with a walking frame
and lived independently again (EDSS 6.5).
Three months later, she developed cytomegalovirus
pneumonia and hepatopathy, probably related to azathio-
prine. At the time of admission, she had normal leukocyte
counts and moderate lymphopenia (11 % e 570/ll).
Azathioprine was discontinued. She recovered completely
after receiving ganciclovir. Immunosuppression was swit-
ched to mycophenolate mofetil which is well tolerated
(1.5 g/d). Until now, she has remained relapse-free for
2 years.
Case 2
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(b) T2
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e
Case 1
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Fig. 1 MRI scans of case 1–3
showing longitudinally
extensive spinal cord lesions.
Yellow solid arrows indicate
extensions of lesions. The lesion
extended throughout the entire
myelon and there were also
lesions in the brainstem in case
1 (a) (upper inset in a). Blue
dashed lines in the sagittal
images indicate the levels of
related axial scans. med. obl.
axial scan at level of medulla
oblongata, C and T indicate the
respective cervical and thoracic
vertebrae; T2 T2 weighed MRI
sequence, T1 T1 weighed MRI
sequence, ?Gd gadolinium-
enhanced sequence
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Conclusions
According to independent cohorts, the mean onset of
NMO is around 40 years [1, 2]. We report three patients
who were much older at the time of first manifestation,
so that initially NMOSD was considered unlikely. Pa-
tients with very late-onset NMOSD ([75 years) have
hitherto only rarely been reported in detail, and case 2
is, to our knowledge, the oldest patient described so far
(Table 1).
Of note, all our patients initially presented with myelitis.
More frequent myelitis (vs. optic neuritis) as initial pre-
sentation is consistent with recent reports for patients with
late-onset ([50–60 years) from Europe, USA and Japan
[6–9] (see also Table 1). Interestingly, also multiple scle-
rosis late-onset patients had more often spinal cord lesions
compared to young-onset (\50 years) patients [10].
Both patients (case 1 and 2) who did not receive im-
munosuppression after their first attack experienced one
or more subsequent relapses shortly afterwards, and case
1 who never received immunosuppression had a fulminant
course and died of NMO sequelae within 1 year from
disease onset. An older age at onset was associated with
earlier death due to myelitis and infection [6]. Unlike in
multiple sclerosis, relapse activity in NMO does not seem
to decrease with age; even very old patients are at risk of
further disabling attacks (our cases, ref [11], and Table 1).
This suggests that also patients with late-onset need long-
term prophylactic treatment to prevent subsequent
relapses.
The benefits of an immunosuppressive therapy have to
be weighed against an increased risk of adverse effects in
the elderly. Clearly, attention and alertness is warranted
especially in older individuals to recognize adverse effects
as early as possible. Further NMOSD treatment studies
should pay special attention to patients with late-onset.
In all three cases, NMOSD initially was not considered
as the first-line diagnosis, mainly because of the old age
and past medical history. In this age group, seemingly
competing explanations of myelon lesions are common,
including vascular, infectious, and orthopedic causes, as
initially falsely suspected also here. However, delayed di-
agnosis and treatment can lead to subsequent relapses and
fatal outcome. Therefore, it is mandatory to consider
NMOSD irrespective of age and past medical history in
patients with a compatible syndrome, especially longitu-
dinally extensive myelitis. The diagnostic workup should
include MRI, CSF investigations including differential cell
count, serum AQP4-Ab testing using recombinant cell-
based assays, and electrophysiology to detect and treat
NMOSD as early as possible.
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Table 1 Screening Pubmed for NMOSD cohorts and case reports with at least 1 patient with onset[60 years did not reveal patients at least as
old as our NMOSD patient with very late-onset at 88 years. Onset[50 years is usually defined already as late-onset
Location/ethnicity
(age limit for study inclusion)
Number of
patients
Max. onset
(age in years)
Clinical characteristics References
Korea (–) 92 63 Patients with onset[50 year (22 %): more often
myelitis onset and higher ARR
[7]
France, 87 % Caucasian (–) 125 66 20 % onset[50 year [12]
Anglo-Saxon Americans and
Hispanic Americans (–)
8 73 Oldest patient with ON onset. No LTI, relapse after
4 months, fatal course
[13] (before
AQP4-Ab)
Australia (–) 71 79.6 Patients with onset[50 year: less often optic neuritis
onset
[9]
Europe, 93 % Caucasian
(late-onset NMOSD[50 year)
108 82.5 Myelitis onset in 67 %. Mean follow-up 4.6 year, 82 %
with relapses
[6]
Japan (–) 583 86 Patients with onset[60 year: more often myelitis onset [8]
Italy (late-onset case report) 1 64 Optic neuritis and myelitis onset. Two relapses within
months, fatal course
[14] (before
AQP4-Ab)
USA (late-onset case report) 1 69 Optic neuritis and myelitis onset [15] (before
AQP4-Ab)
France (late-onset case report) 1 77 Myelitis onset. W/o LTI, relapse after 1 year [16]
USA (late-onset case report) 1 81 Brainstem and myelitis onset. No LTI, several relapses
and death within about 1 year
[17] (before
AQP4-Ab)
USA (late-onset case report) 1 85 Myelitis onset, no long-term follow-up [18]
ARR annualized relapse rate, before AQP4-Ab study performed before availability of AQP4-Ab testing, LTI long-term immuno-suppressive
therapy
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iskrankenhaus Bad Pyrmont gGmbH; R. Linker, University
of Erlangen; W. Marouf, Heliosklinik Stralsund; M.
Marziniak, Isar-Amper Klinik Ost Munich; I. Metz,
University of Go¨ttingen; C. Mayer, University of Frank-
furt; A. Melms, University of Erlangen; C. Mu¨nch, Charite´
University Medicine Berlin; O. Neuhaus, Kreiskranken-
haus Sigmaringen; S. Niehaus, Klinikum Dortmund; F.
Pache, Charite´ University Medicine Berlin; F. Paul, Charite´
University Medicine Berlin, H. Pellkofer, University of
Go¨ttingen; R. Reuss, Bezirkskrankenhaus Bayreuth; A.
Riedlinger, Asklepios Klinik Teupitz; M. Ringelstein,
University of Du¨sseldorf; S.P. Rommer, University of
Rostock; K. Ruprecht, Charite´ University Medicine Berlin;
S. Schippling, University of Zu¨rich (Switzerland); S.
Schuster, University of Tu¨bingen; M. Schwab, University
of Jena; M. Stangel, Medizinische Hochschule Hannover,
J. Stellmann, University of Hamburg; F. Then-Bergh,
University of Leipzig; C. Trebst, Medizinische Hochschule
Hannover; H. Tumani, University of Ulm; C. Veauthier,
Heliosklinik Stralsund; KP. Wandinger, University of
Schleswig–Holstein; R. Weissert, University of Regens-
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